0000947871-21-000395.txt : 20210326
0000947871-21-000395.hdr.sgml : 20210326
20210326174655
ACCESSION NUMBER: 0000947871-21-000395
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210324
FILED AS OF DATE: 20210326
DATE AS OF CHANGE: 20210326
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GORDON CARL L
CENTRAL INDEX KEY: 0001282930
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39269
FILM NUMBER: 21778802
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001796280
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 471787157
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 240 E. GRAND AVE.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 388-5600
MAIL ADDRESS:
STREET 1: 240 E. GRAND AVE.
STREET 2: 2ND FLOOR
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
ownership.xml
X0306
4
2021-03-24
0
0001796280
Oric Pharmaceuticals, Inc.
ORIC
0001282930
GORDON CARL L
C/O ORBIMED ADVISORS LLC
601 LEXINGTON AVENUE, 54TH FLOOR
NEW YORK
NY
10022-4629
1
0
0
0
Common Stock
2021-03-24
4
S
0
32959
24.80
D
2395334
I
See Footnotes
Common Stock
2021-03-25
4
S
0
51523
24.70
D
2343811
I
See Footnotes
Common Stock
2021-03-26
4
S
0
27816
23.88
D
2315995
I
See Footnotes
These shares of the Issuer's common stock were sold in a block order at a price of $24.80 pursuant to a Rule 10b5-1 trading plan established by OrbiMed Private Investments VI, LP ("OPI VI").
These shares of the Issuer's common stock are held of record by OPI VI. OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
Each of the Reporting Person, OrbiMed Advisors, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or GP VI is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
These shares of the Issuer's common stock were sold in a block order at a price of $24.70 pursuant to a Rule 10b5-1 trading plan established by OPI VI.
These shares of the Issuer's common stock were sold in a block order at a price of $23.88 pursuant to a Rule 10b5-1 trading plan established by OPI VI.
/s/ Carl L. Gordon
2021-03-26